Cradle-to-grave life cycle assessment of packaging material for a pharmaceutical company
- Authors: Sipuka, Siphokazi
- Date: 2018-04
- Subjects: Drugs -- Packaging , Drugs -- Packaging -- Quality control , Drugs -- Design
- Language: English
- Type: Master's theses , text
- Identifier: http://hdl.handle.net/10948/66533 , vital:75588
- Description: Due to anthropogenic activity as a result of the industrial revolution, the earth’s climate has changed drastically and key decision makers, including the public, have begun to recognize the need for action to be taken in order to curb global warming (Goodall, 2007). Businesses, policymakers and governments have been tasked with finding means and ways to reduce greenhouse gas (GHG) emissions. The need to better understand the activities that drive GHG emissions and how they can successfully be reduced has become strategic for various organisations (Business Gateway, 2012). The carbon footprint concept was born as a result of the need for a tool to estimate GHG emissions (Wiedmann and Minx, 2007). The primary objective of this research study was to determine the level of awareness of the environmental carbon footprint within the various functional units including procurement, planning, packaging, production, logistics, projects, quality and safety, health and environment of the packaging supply base. The aim was to also gain insight into whether the carbon footprint is taken into consideration during the packaging design stage, as well as to understand the level of carbon footprint quantification currently being conducted by the various functional units within packaging organisations. Pharmaceutical packaging represents a significant percentage of the carbon footprint emissions and is possibly the single largest contributor of carbon footprint emissions in various organisations’ value chain (Business Gateway, 2012). An empirical study was conducted using a questionnaire in a sample of fifty key strategic packaging suppliers who manufacture both locally and abroad. Data analysis was conducted in order to investigate the primary objectives of the research study. The key findings and recommendations to the organisations' management are presented in the study. , Thesis (MBA) -- Faculty of Business and Economic Sciences, Business School, 2018
- Full Text:
- Date Issued: 2018-04
- Authors: Sipuka, Siphokazi
- Date: 2018-04
- Subjects: Drugs -- Packaging , Drugs -- Packaging -- Quality control , Drugs -- Design
- Language: English
- Type: Master's theses , text
- Identifier: http://hdl.handle.net/10948/66533 , vital:75588
- Description: Due to anthropogenic activity as a result of the industrial revolution, the earth’s climate has changed drastically and key decision makers, including the public, have begun to recognize the need for action to be taken in order to curb global warming (Goodall, 2007). Businesses, policymakers and governments have been tasked with finding means and ways to reduce greenhouse gas (GHG) emissions. The need to better understand the activities that drive GHG emissions and how they can successfully be reduced has become strategic for various organisations (Business Gateway, 2012). The carbon footprint concept was born as a result of the need for a tool to estimate GHG emissions (Wiedmann and Minx, 2007). The primary objective of this research study was to determine the level of awareness of the environmental carbon footprint within the various functional units including procurement, planning, packaging, production, logistics, projects, quality and safety, health and environment of the packaging supply base. The aim was to also gain insight into whether the carbon footprint is taken into consideration during the packaging design stage, as well as to understand the level of carbon footprint quantification currently being conducted by the various functional units within packaging organisations. Pharmaceutical packaging represents a significant percentage of the carbon footprint emissions and is possibly the single largest contributor of carbon footprint emissions in various organisations’ value chain (Business Gateway, 2012). An empirical study was conducted using a questionnaire in a sample of fifty key strategic packaging suppliers who manufacture both locally and abroad. Data analysis was conducted in order to investigate the primary objectives of the research study. The key findings and recommendations to the organisations' management are presented in the study. , Thesis (MBA) -- Faculty of Business and Economic Sciences, Business School, 2018
- Full Text:
- Date Issued: 2018-04
Cost comparison between repackaging bulk oral solid medicines and purchasing manufacturer-prepared patient-ready packs in the public sector in South Africa
- Authors: Abahamye, Aloysius
- Date: 2014
- Subjects: Packaging -- Cost control , Business logistics -- Costs , Drugs -- Packaging , Manufacturing processes
- Language: English
- Type: Thesis , Masters , MPharm
- Identifier: vital:10163 , http://hdl.handle.net/10948/d1020596 , Drugs -- Packaging
- Description: In an attempt to have medicines available in patient-ready packs (PRPs) prior to the dispensing process, the provincial medicine depots in South Africa have, for many years, been repackaging bulk medicines into PRPs. Notwithstanding the fact that bulk medicine packages may have been the only packages available from the manufacturers to service the Primary Health Care (PHC) sector, the main aim of this process was to ensure that medicines were available in PRPs for dispensing to patients, thus, minimising the time spent on each prescription by the pharmacist, pharmacist’s assistant or Nurse. Currently, some medicines are being procured in PRPs from the manufacturers, whereas others are still procured in bulk packs which must be repackaged into PRPs. After a thorough literature search, it was established that, up until this point in time, no studies have been performed to compare costs of repackaged medicines from bulk packs with costs of medicines procured from manufacturers in PRPs. There was very scanty literature comparing the use of medicines procured either in PRPs or bulk packs. However, literature on cost comparison between repackaging and purchasing of commercially available manufacturer-prepared PRPs was not identified.
- Full Text:
- Date Issued: 2014
- Authors: Abahamye, Aloysius
- Date: 2014
- Subjects: Packaging -- Cost control , Business logistics -- Costs , Drugs -- Packaging , Manufacturing processes
- Language: English
- Type: Thesis , Masters , MPharm
- Identifier: vital:10163 , http://hdl.handle.net/10948/d1020596 , Drugs -- Packaging
- Description: In an attempt to have medicines available in patient-ready packs (PRPs) prior to the dispensing process, the provincial medicine depots in South Africa have, for many years, been repackaging bulk medicines into PRPs. Notwithstanding the fact that bulk medicine packages may have been the only packages available from the manufacturers to service the Primary Health Care (PHC) sector, the main aim of this process was to ensure that medicines were available in PRPs for dispensing to patients, thus, minimising the time spent on each prescription by the pharmacist, pharmacist’s assistant or Nurse. Currently, some medicines are being procured in PRPs from the manufacturers, whereas others are still procured in bulk packs which must be repackaged into PRPs. After a thorough literature search, it was established that, up until this point in time, no studies have been performed to compare costs of repackaged medicines from bulk packs with costs of medicines procured from manufacturers in PRPs. There was very scanty literature comparing the use of medicines procured either in PRPs or bulk packs. However, literature on cost comparison between repackaging and purchasing of commercially available manufacturer-prepared PRPs was not identified.
- Full Text:
- Date Issued: 2014
- «
- ‹
- 1
- ›
- »